Hepatic and intestinal transplantation at the University of Pittsburgh. by Abu-Elmagd, K et al.
)010 
CHAPTER 24 
Hepatic and Intestinal Transplantation at The 
University of Pittsburgh 
Kareem Abu-Elmagd, John Fung, Jorge Reyes, Abdul Rao, Ashok Jain, 
263 
George Mazariegos, Wallis Marsh, Juan Madariaga, Igor Dvorchik, Javier Bueno, 
Jeffrey Rogers, John McMichael, Forrest Dodson, Hugo Vargus, John Martin, 
Adam Slivka, Vijay Balan, Robert Corry, Jorge Rakela, Noriko Murase, 
Jake Demetris, Shunzaburo Iwatsuki, and Thomas Starzl 
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center 
Pittsburgh, Pennsylvania 
The last 4 decades of this century have witnessed 
the evolution of liver and other organ transplantation to 
a high standard of care for patients with end-stage or-
gan disease. In this chapter, we will focus on what has 
been accomplished at our center in: 1) defining the mean-
ing of organ allograft acceptance and acquired tolerance; 
2) improving survival after liver transplantation, with par-
ticular reference to tacrolimus, drug weaning, and dis-
ease recurrence, 3) applying lessons from liver and other 
organ transplantation to hepatointestinal and 
ORGAN ENGRAFTMENT AND 
ACQUIRED TOLERANCE 
Organ allograft survival has improved stepwise over 
the last 37 years with the successive availability of aza-
thioprine, cyclosporine (CYA) and tacrolimus (TAC), each 
of which has been combined with adjustable doses of 
prednisone or incorporated into more complex multiple 
drug cocktails. However, the prototypical events after 
transplantation (1,2) have remained the same (Fig. 1). 
multivisceral transplantation and 4) assessing 
the feasibility of clinical xenotransplantation. 
PATIENTS AND METHODS 
The patient and graft survival curves for 
all of the clinical studies were generated us-
ing the Kaplan-Meier method; group compari-
sons were done using the log-rank test. The 
cumulative risks of rejection and graft loss from 
rejection were also estimated using the 
Kaplan-Meier method. Risk factors for mor-
tality, graft loss, and morbidity were analyzed 
using Cox's proportional hazards and the arti-
ficial neural network models. Continuous vari-
ables were presented as mean ± standard de-
viation and categorical data as proportions. 
Differences between group means were tested 
using the standard two-tailed sample t-test and 
differences in proportions by Fisher's exact 
test. 
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Figure 1. The 4 events that occur in close temporal approxima-
tion when there is successful organ engraftment: above, double 
acute clonal exhaustion (1,2) and subsequent maintenance 
clonal exhaustion (3) plus, below, loss oforgan immunogenicity 
due to depletion of the graft's passenger leukocytes (4) (From 
Tholllas E. Starzl: The art o/tolerance. Nature Med. 1998. 
4: 1006-1007, used by permission). 
Clinical Transplants 1998, Cecka and Terasaki, Eds. UCLA Tissue Typing Laboratory, Los Angeles, California 
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In successful cases, the host response against the graft, 
which mayor may not be strong enough to cause clini-
cal and/or histopathologic findings of rejection, is followed 
by a reduced need for immunosuppression. 
It was generally assumed for more than 3 decades 
that the foregoing events leading to organ allograft ac-
ceptance involved different mechanisms than the neo-
natal tolerance of Billingham, Brent, and Medawar or the 
acquired tolerance of cytoablated recipients of bone 
marrow allografts. However, studies following the dis-
covery of small numbers of donor leukocytes 
(microchimerism) in the tissues and blood of human or-
gan recipients many years after transplantation (3,4) have 
shown that the essential mechanisms of organ engraft-
ment are the same under all 3 circumstances (5-7). 
After organ transplantation, most of the donor leu-
kocytes of bone marrow origin that are contained in the 
allograft migrate primarily to host lymphoid organs. This 
results not only in progressive loss of the allograft's an-
tigenicity, but also in the initiation by the peripheralized 
donor cells of reciprocal acute clonal activation of the 
usually dominant host-versus-graft (HVG) response and 
the graft-versus-host (GVH) response of the passenger 
leukocytes (Fig. 1). With successful engraftment, these 
proceed to mutual clonal exhaustion-depletion (3,7). 
Maintenance of the exhaustion-deletion is depen-
dent on persistence of the donor leukocytes, small num-
bers of which escape primary destruction in the lymphoid 
organs and secondarily migrate to non-lymphoid sites 
where they may periodically return to host organized lym-
phoid organs or ectopic collections. The delayed leak-
age of donor leukocytes from the non-lymphoid to the 
lymphoid compartment is thought to represent a balance 
between destructive and non-destructive immunity as has 
been demonstrated experimentally in autoimmune dia-
betes models (8). The events after successful bone 
marrow transplantation to a cytoablated recipient are the 
same, but in mirror image, ie., the dominant immune sys-
tem is the donor's (5-7). 
The 2 mechanisms of clonal exhaustion-deletion and 
immune indifference are governed by antigen migration 
and localization (7) and proceed to permanent engraft-
ment without therapy in a limited number of animal mod-
els, especially when the transplanted organ is the leuko-
cyte-rich liver (6). Under most circumstances, however, 
immunosuppression is required to prevent one cell popu-
lation from destroying the other before the tolerogenic 
events shown in Figure 1 can occur. 
Although this principle was not understood, its ex-
ploitation with azathioprine, combined with adjustable 
doses of prednisone (1), established an empirical basis 
for the field of clinical organ transplantation that has been 
exploited with progressively greater efficiency using 
baseline therapy with CYA and T AC for all organs, in-
cluding the liver (Fig. 2) (9). In addition to explaining 
iij100 
> 
K~ 80 
;::, 
CJ) 
... 
s::: 
(!) 
;; 
ctS 
Q. 
... 
s::: (!) 
~ 
(!) 
Q. 
60 
40 
20 
0 
100 
(ij 
> 80 K~ 
;::, 
CJ) 60 
¢: 
ctS 
~ 40 (!) 
... 
s::: 20 (!) ~ 
(!) 
Q. 0 
0 
0 
1 2 
n 
• TAe 1,391 
~ eYA 1,835 
• AZA 168 
3 4 
Years Posttransplant 
n 
• TAe 1,582 
~ eYA 2,416 
• AZA 190 
1 234 
Years Posttransplant 
5 
5 
Figure 2. Patient and graft survival during the 30-
year history of the liver transplantation program at 
the University of Colorado (1963-1980) and 
Pittsburgh (/981-1993). The eras were defined by 
major improvements. The dates of case accrual 
from bottom to top were 1963-/979 (Croup 1), 
1980-/989 (Croup 2), and /989-1993 (Croup 3). 
Croup 2 and 3 had sign ifican tZv better survival 
(p<O. 00 1). AZA =azathioprine, CYA =cyclosporine, 
FK-506=TAC (From Todo S. Fung J, Starz! TE, et 
al. Single-center experience with primary orthotopic 
liver transplantation with FK-506 immunosuppres-
sion. Alln ofSlIrg, 1994: 220,297-309. 
transplantation enigmas of the past, this concept has 
dominated our plans for future research and develop-
ment as will be evident in the succeeding sections, 
LIVER TRANSPLANTATION 
The Impact of Tacrolimus 
On Patient and Graft Survival- In the 1995 edi-
tion of this book, we discussed the high therapeutic in-
dex and relatively short-term survival benefits of TAC as 
the primary baseline immunosuppressive agent (Fig, 2) 
for liver allograft recipients based on our own experi-
ence (9,10,11), as well as the data of both the American 
(12) and European randomized studies (13), The re-
sults unequivocally proved that T AC is a more potent 
and satisfactory immunosuppressant than CYA, In the 
multicenter European and American randomized trials 
as in our single-center trial, the ability of T AC to rescue 
intractably rejecting grafts in patients treated primarily 
with CYA (9-15) allowed equalization of patient and graft 
survival on both arms of the randomized trials when the 
intent-to-treat analytic methodology was applied, How-
ever, the ability of TAC to systematically rescue the treat-
ment failures of CYA and to then be continued perma-
nently suggested that it was the preferred baseline drug 
for hepatic transplantation (and all organs). This con-
clusion was supported by analysis of secondary end 
points. 
To further document the safety and long-term effi-
cacy of T AC, we recently analyzed the results of the first 
1,000 primary liver allograft recipients who were trans-
planted between August 1989-December 1992 and were 
followed until August 1997 (16). Of these 1,000 con-
secutive patients, 7.5% were infants, 9.1 % were children, 
63% were adults (aged 19-60), and 20.4% were aged 
60 or older (Table1). Eighty-four percent of these recipi-
ents were hospital bound at the time of transplantation. 
Livers from older donors (over age 50) were used in 141 
cases. 
With a mean follow-up of 6.4 years (range: 4.7-8), 
the overall patient and graft survival rates at 7 years were 
65% and 60%, respectively (Fig. 3). Patient and graft 
survival rates were best among reCipients aged 2-18 with 
a 7-year patient survival rate of 91 % and graft survival of 
85%. The differences in both patient (Fig. 4A) and graft 
(Fig. 48) survival among the 4 age cohorts were statisti-
cally significant (p<0.001). The common causes of long-
term patient/graft loss (particularly in the adult and se-
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Table 1. Clinicalfeatures of the first 1,000 conSectl-
tive patients who received primary liver transplanta-
tion under tacrolimus based immunosuppression 
during the period from August 1989-December 1992. 
No. of Patients (%) 
Total 1,000 
Sex (M/F) 600/400 
Age (yr) 
Infants E~OF 75 (75%) 
Children E>O~1UF 91 (9.1%) 
Adults E>1U~SMF 630 (63%) 
Seniors (>60) 204 (20.4%) 
Indications for transplants 
Nonalcoholic cirrhosis 341 (34.1%) 
Alcoholic cirrhosis 188 (18.8%) 
Biliary atresia 86 (8.6%) 
Primary biliary cirrhosis 83 (8.3%) 
Primary sclerosing cholangitis 60 (6%) 
Primary hepatic malignancy 79 (7.9%) 
Acute fulminant failure 34 (3.4%) 
Miscellaneous 129 (12.9%) 
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Figure 3. The cumulative survival of the first 1, 000 
consecutive patients who received primary liver 
transplantation under TAe-based immunosuppres-
sion. 
7 
nior population) were primary disease recurrence, car-
diopulmonary failure, cerebrovascular accidents, non-
compliance, and de novo malignancy. 
The level of T AC-steroid maintenance immunosup-
preSSion is depicted in Figure 5. It is important to note 
that the daily TAC dose was gradually reduced and that 
the whole blood drug trough level was maintained below 
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Figure 4. The Kaplan-Meier patient (Aj and graft (Bj survival according to age. 
10 ng/ml with long-term follow-up. Equally im-
portant, complete weaning from steroids was 
achieved in 53% and 67% of the recipients at 
3 months and 5 years after transplantation. 
Despite the lightened maintenance immuno-
suppression, only 1.6% of the grafts were lost 
due to chronic rejection. In most of these ex-
ceptional cases, T AC had been reduced or 
stopped because of life-threatening infections 
(eg. hepatitis C or B, cytomegaloviral disease) 
or patient noncompliance (15). 
Tacrolimus Toxicity - The early and 
long-term overall estimated risk of hyperten-
sion requiring anti-hypertensive medication, 
insulin dependent diabetes. and hyperkalemia 
are shown in Table 2. There was a slight in-
crease in the mean serum cholesterol levels 
with long-term follow-up. An initial increase in 
serum creatinine during the first 3 postopera-
tive months was maintained without further 
deterioration in kidney function in most recipi-
ents. Only 2% of the pediatric population and 
4% of the adult patients including senior re-
cipients developed end-stage renal failure and 
required dialysis and or kidney transplantation. 
De Novo Malignancies - Posttransplant 
Iymphoproliferative disease (PTLD) developed 
in a total of 35 (3.5%) patients. The incidence 
was higher among the pediatric (11.4%) than 
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Figure 5. The TAe dose, drug trough level, and prednisone dose 
during the first 5 years after liver transplantation. 
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Table. 2. Tacrolimus adverse effects. serum creatinine and cholesterol levels among primary liver allograft 
recIpIents. 
Follow-up Hypertensiona Diabetesb Hyperkalemiac Serum Creatinine Serum Cholesterol 
(mean mg/dl) (mean mg/dl) 
3 months 29% 24% 39% 1.7 102 
6 months 29% 13% 44% 1.7 159 
1 year 30% 16% 42% 1.7 165 
5 years 46% 18% 35% 1.7 178 
a Requiring antihypertensive medication, b Insulin dependent, C K+ >5.0 mEq/L 
the adult (1.9%) population and was associated with 
a 21% and 31 % mortality, respectively. De novo non-
lymphoid malignancy was observed in 57 patients, 
all adults, for an overall incidence of 5.7% (6.8% for 
adults) (17). The malignancies were lethal in 58% of 
these cases. The type and/or site of malignancy and 
its frequency compared with the general population 
are shown in Figure 6. Skin cancers were the most 
common (2.2%) type of de novo non-lymphoid malig-
nancy but had the best long-term survival. The rela-
tive risk of developing oropharyngeal cancer was 7.6 
times higher and lung cancer was 1.7 times higher 
than in the general population matched for age, gen-
der, and length of follow-up. The cumulative risks of 
PTLD and de novo malignancy are comparable with 
azathioprine and CYA-based regimens (18,19). 
Pregnancy - Childbearing, which was an un-
usual event after liver transplantation under previous 
immunosuppressive regimens, has been common in 
women treated with T AC. The maternal and fetal risk 
of pregnancy after liver transplantation and under TAC 
was prospectively studied in 27 pregnancies among 
21 female recipients (20). The 21 mothers had sur-
prisingly few serious complications of pregnancy and 
no mortality, in contrast to previous experience with aza-
thioprine and CYA-based immunosuppression. Preg-
nancy was possible with a very low incidence of hyper-
tension, pre-eclampsia, abnormal allograft function, and 
other maternal complications historically associated with 
such gestations. 
No allograft loss was attributed to pregnancy. As in 
previous experience with other immunosuppressive regi-
mens, preterm deliveries and spontaneous renal impair-
ment of the infants were common (20). However, pre-
natal growth for gestational age and postnatal infant 
growth for postpartum age were normal. The 2 infant 
losses in our series were by mothers whose conceptions 
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Figure 6. Frequency of distribution of various malignan-
cies among liver recipients treated with TAC compared 
with the general population (From Jain AB, Yee LD, 
Nalesnik MA, et al: Comparative incidence of de novo 
nonlymplzoid malignancies after liver transplantation 
under TAC using surveillance epidemiologic end result 
data. Transplantation 1998. 66:1193-1200, used by 
permission). 
were temporally close to liver transplantation. There-
fore, it is our practice to advise women of child bearing 
age to avoid pregnancy for 2 years after hepatic trans-
plantation and for longer when there have been trans-
plant-related management problems including steroid 
dependence. 
More Complex Regimens - Addition of adjunct 
maintenance immunosuppressive agents has not added 
survival benefits. Over the past 3 years, a prospective 
randomized trial of TAC and prednisone versus TAC, 
prednisone, and mycophenolate mofetil (MMF) in primary 
adult liver transplant recipients was conducted at our cen-
ter (21). A total of 300 patients were enrolled; 151 in 
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Figure 7. Kaplan-Meier actuarial patient (AJ and graft (8) survival curves for TAC and steroids (double) 
therapy versus TAC. steroids and mycophenolate lIlofeti! (triple) therapy. 
double-drug therapy and 149 in triple-drug therapy. 
During the study period and as of June 1998, 35 (23.2%) 
of the double-drug therapy patients had MMF added to 
control ongoing acute rejection, nephrotoxicity, and/or 
neurotoxicity. On the other hand, 83 (55.7%) patients in 
the triple-drug therapy cohort discontinued MMF for in-
fection (18.5%), myelosuppression (15.9%), gastrointes-
tinal disturbances (13.9%), and other reasons (6.6%). 
With a mean follow-up of 24.7 months (range: 3.7-
29) and by an "intent-to-treat analysis", the actuarial 2-
year patient survival rate was 83% with double-drug 
therapy and 85% with triple-drug therapy (Fig. 7 A) with 
a graft survival rate of 76% and 78%, respectively (Fig. 
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78). The difference between the 2-year rejection-free 
rate of each cohort was also not statistically significant 
with an incidence of 67% (triple-drug) and 58% (double-
drug). The mean maintenance steroid dose, however, 
was slightly lower with triple-drug compared with double-
drug therapy. The rates of postoperative infection, 
perioperative hematological changes, and gastrointesti-
nal side effects were similar in both groups but with bet-
ter preservation of renal function among the triple-drug 
therapy group (21). 
Drug-Free Liver Graft Acceptance: 
The Weaning Trial 
Despite the increase in the cumula-
tive survival rate of liver allograft recipi-
ents over the last 15 years at our center 
(Fig. 8) and elsewhere (particularly since 
1989), the maintenance immunosuppres-
sion, which has been assumed to be a 
permanent requirement, is associated with 
complications that range from trivial to le-
81 82 83 84 85 86 87 88 89 90 91 92 93 94 
Year 
Figure 8. The yearly cumulative increase 
in the patient survival at one, 2 and 5 
years after liver transplantation at the 
95 University of Pittsburgh during the last 15 
years. 
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thaI. When evidence of chimerism in long-surviving kid-
ney, liver, and other organ recipients was discovered in 
1992, a linkage was established between organ allograft 
acceptance, and the acquired neonatal tolerance of 
Billingham, Brent and Medawar as well as the cytoablated 
drug-free recipient of bone marrow allograft (3-7) (see 
section on "Organ Engraftment and Acquired Tolerance') 
Because the engraftment of organs involves the 
transplantation of a small fragment of the donor immune 
system (ie., the passenger leukocytes), it was consid-
ered possible that the resulting chimerism-dependent 
tolerogenic process no longer required the assistance 
of immunosuppression. In fact, it was learned in the 
course of the chimerism studies that several of our pa-
tients who included the longest surviving liver and kid-
ney recipients in the world had secretly stopped their 
medications - some for as long as 30 years (4). Con-
sequently, a prospective weaning trial was begun in liver 
recipients as extensively discussed in 1995 edition of 
this book and recently updated elsewhere (22,23). 
A total of 95 liver recipients was entered into the 
prospective weaning series between June 1992-April 
1996 (23). The criteria for admission were: 1) ~ 5 years 
posttransplantation, 2) ~ 2 years rejection free, 3) com-
pliance of both patient and local physician, 4) absence 
of acute/chronic rejection, and primary disease recur-
rence in a baseline liver biopsy, and 5) exclusion by im-
aging or interventional radiologic techniques of vascular 
or biliary tract complications. Thirty-one (33%) patients 
were children (--s age 20), and 64 (67%) were adults 21-
68 years old. The leading causes of pretransplant 
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included hypertension (n=32), renal insufficiency (n=27), 
skin lesions/malignancy (n=12), neurologic disorders 
(n=4), infection (n=6), steroid-related complications (n=9), 
and diabetes (n=9). Thirty-seven (39%) patients had 
multiple immunosuppression-related complications. The 
details of the weaning protocol, monitoring of graft func-
tion, and rescue treatment in the event of rejection are 
described elsewhere (22,23). 
Graft loss - No grafts were lost to weaning, al-
though 2 patients died with normally functioning organs. 
The first death was from septic pulmonary complications 
of cystic fibrosis, while still weaning. The second pa-
tient, who had been returned to baseline immunosup-
pression following an easily controlled mild acute cellu-
lar rejection, died of a pulmonary embolus following com-
plications of a severe foot infection. These deaths were 
directly attributable to the morbidity of chronic immuno-
suppression, which the weaning protocol was designed 
to ameliorate. 
Success of Weaning - Eighteen (19%) of the 95 
patients have been drug free with normal liver function 
tests for 10-58 months. The success rate was higher in 
children than adults (Fig. 9). There was no significant 
difference in the success rate when the baseline immu-
nosuppressant was T AC or azathioprine. However, there 
was a significant difference between these groups and 
all of the CYA-based regimens (P--s 0.003). Azathioprine/ 
prednisone-based patients were more likely to be off 
drugs at one year as compared with CYA-based patients 
(p<0.001). TAC-based patients enjoyed a similar advan-
liver failure were biliary atresia in children and 
viral/autoimmune hepatitis, cholestatic liver dis-
ease and alcoholic/cryptogenic cirrhosis in adults. 
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The immunosuppression at the start of wean-
ing was azathioprine-based in 13 (13.5%), CYA-
based in 71 (75%) and TAC-based in 11 (11.5%) 
cases. Except for the TAC era, initial triple-drug 
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therapy had been used throughout the 30-year 20 
period of our program (Colorado/Pittsburgh), al-
ways involving prednisone as the secondary 10 
drug, but with the variable use of azathioprine 
and ALG/OKT3 as third or fourth agent (9). Pred-
nisone was the only adjunct drug in most of the 
patients treated from the outset with T AC. With 
a mean time from liver replacement to the start 
of weaning of 8.4 .! 4.4 years, complications of 
long-term immunosuppression prior to weaning 
O-lr-......... -
Pediatric Adult 
Figure 9. The results of the weaning trial among the pediatric 
and adult population (From lvfazariegos G V, Reyes J, Marino 
fR, et al: Weaning o!immwlOsuppression in h\'er transplant 
recipients. Trallsplantation J 997, 63:243-249, used by permis-
sion). 
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tage (p=O.003). Figure 10 illustrates the cumulative per-
cent of patients off immunosuppression at one year. 
Another 37 (39%) patients are currently in the unin-
terrupted process of drug weaning with a mean percent-
age decrease in baseline immunosuppression (mg/day) 
of 44 ± 31 for TAC, 30 ± 35 for CYA, 14 ± 88 for pred-
nisone, and 13 ± 33 for azathioprine. 
Interruption of weaning occurred in the remaining 
40 (42%) patients; 28 because of rejection and 12 be-
cause of withdrawal from the protocol. The rejection was 
histologically documented in 21 of these recipients (18 
acute and 3 incipient chronic) and clinically suspected in 
the other 7. Withdrawal from the weaning protocol was 
due to noncompliance (n=8), pregnancy (n=1), kidney 
transplantation (n=1), and recurrent primary biliary cir-
rhosis (n=2). The non-compliant cases were maintained 
at whatever level of treatment had been reached at the 
time the decision to stop weaning was made. All 8 of 
these recipients were well at the time and remain so. 
The Clinical Benefits of Drug Withdrawal - The 
achievement of a drug-free state (n=18) did not signifi-
cantly improve either renal function or pre-existing hy-
pertension. The most common benefits were resolution 
of gingival hyperplasia in 2 children, resolution of infec-
tions in 3, resolved PTLD in 3, and relief of neuropsychi-
atric complaints in 2 recipients. 
The Differential Diagnosis of Graft Dysfunction 
- During the study period, significant elevation in AST, 
AL T, and GGTP occurred in 44 (46%) patients followed 
by liver biopsy in 37. The biopsy findings were acute 
cellular rejection (n=18), minor duct injury (n=3), hepati-
tis (n=3), normal histology (n=7), evidence of biliary tract 
obstruction (n=3), nonspecific portal inflammation (n=2), 
and steatosis (n=1). Rejection, which was diagnosed 
by biopsy in 18 (19%) of the 95 patients occurred at a 
mean time of 13.2 months after the start of weaning and 
was graded as mild or moderate by histopathologic cri-
teria described in detail elsewhere (11). Treatment con-
sisted of pulse steroids with resumption of the baseline 
immunosuppressive therapy in 15 patients and conver-
sion from CYA to T AC in 3 patients with moderate rejec-
tion. None of the patients required OKT3. 
Seven additional patients were diagnosed without 
biopsy as having acute rejection. Because the liver in-
jury tests were normalized after the increase of 
immunosupppression, they were arbitrarily included in 
the acute rejection category. There were no infectious 
complications following treatment for rejection except for 
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Figure J O. The effect of the baseline immunosup-
pression on the cumulative rate of complete drug 
withdrawal (From Mazariegos GV, Reyes J, Marino 
JR, et af: Weaning of immunosuppression in liver 
transplant recipients. Transplantation 1997, 
63:243-249, used by permission). 
one example of herpes stomatitis that was successfully 
managed with anti-viral therapy. 
Chronic rejection was suspected in 3 (3%) cases 
based upon the development of de novo histopathologic 
findings during weaning. The previous level of immuno-
suppression was restored in 2 patients and T AC was 
started in the third, who had been weaned from azathio-
prine. None of the patients developed further evidence 
of chronic rejection. 
Three (3%) patients developed biopsy evidence, 
during weaning, of recurrent (n=2) or de novo (n=1) viral 
C hepatitis. Weaning has continued in these patients 
with stabilization of liver injury tests. 
Two (15%) out of a total of 13 recipients who en-
tered the study 7 and 8 years after transplantation for 
primary biliary cirrhosis developed recurrent disease. 
The diagnosis was histopathologically documented 7 and 
24 months after the initiation of weaning. Liver function 
tests normalized after return to the pre-existing combined 
CY Alsteroid-based immunosuppression. There has 
been no recurrence of other autoimmune hepatic dis-
eases. 
In 3 patients (3%), abnormalliverfunction tests were 
incorrectly attributed to rejection and briefly treated as 
such. After reconstruction of the bile duct, liver enzyme 
values normalized in all 3 recipients and weaning was 
resumed. 
The Impact on Weaning of Prior Treatment- The 
disappointing results with the addition of azathioprine, 
MMF, and other adjunct agents to CYA/prednisone-
based regimens (see earlier) have also been reported 
with kidney transplantation (24). A prime objective of 
these increasingly complex multiple agent cocktails is 
the reduction of the incidence of acute rejection toward 
zero, with the assumption that chronic rejection would 
be commensurately reduced. Instead, the 3-5-year sur-
vival of kidney and liver allografts has had no correlation 
with the incidence of readily controlled acute rejection. 
Only steroid resistant (incompletely reversible) rejection 
has proved to be an early poor prognostic omen. In the 
meanwhile, chronic rejection has emerged as the great-
est unsolved problem in clinical transplantation (25). 
A plausible explanation for this disappointing obser-
vation may be that the immunosuppression which per-
mits a natural tolerogenic succession of the adaptive 
immune response (ie., clonal activation -7 exhaustion 
-7 deletion), carries the penalty of systematically under-
mining this process (see section on "allograft acceptance 
and acquired tolerance"). This explanation is consistent 
with the finding described in the drug weaning trials that 
complete discontinuance of therapy in patients bearing 
long surviving grafts has been consistently possible only 
when the original treatment was with "weak" azathioprine-
based regimens, or when weaning was from simple 
monotherapy with TAC (22,23). 
Donor Leukocyte Augmentation 
The potential anti-tolerogenic role of immunosup-
pression described in the section on drug weaning is 
evident in all transplantation treatment protocols includ-
ing those used for both conventional and adjunct bone 
marrow (8M) transplantation. This reservation notwith-
standing, a persuasive argument can be made for ad-
ministering adjunct donor 8M to organ reCipients on 
grounds that it merely augments the natural mechanisms 
set in motion by the organs migratory "passenger leuko-
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quired tolerance"). If given to non-cytoablated organ re-
cipients at about the same time as the organ transplan-
tation when the immunocompetent donor and recipient 
cells are subject to the same immunosuppression, the 
mutual "nullification" of the 2 cell populations makes the 
infusions safe (3-7). Violation of this principle may have 
caused the death of one of our liver recipients. 
The 8M augmentations were carried out between 
December 1992-September 1998, involving a total of 271 
organ allograft recipients (26). Of these, 229 received a 
single dose of 3-6x10B unmodified donor 8M cells/kg 
body weight and the remaining 42 received multiple in-
fusions (2x108 donor 8M cells/kg body weight! dose) of 
donor 8M during the first 48 hours after transplantation 
in a concurrent protocol. The types of organ transplan-
tation in each study cohort are summarized in Table 3. 
As contemporaneous controls, 133 recipients of liver 
(n=33), kidney (n=47), heart (n=23), lung (n=12), small 
bowel (n=16) and multiple organs (n=2) were also ac-
crued for whom 8M cells were not available. Patient 
characteristics and clinical features were similar for both 
the study (8M augmented) group and control cohorts. 
8M cells were harvested from the vertebral body of the 
cadaveric donors (27) and immunosuppression was with 
TAC and prednisone. MMF but not OKT3 also was given 
to 53 of the study patients and 17 of the control group. 
For steroid-resistant allograft rejection, an anti-CD3 
monoclonal antibody (OKT3) was used. The methods 
utilized for the in vitro monitoring of donor cell chimerism 
and the mixed leukocyte reaction were fully described 
elsewhere (26-28). 
Survival and Immunosuppression - Although 
both single and multiple infusions of unmodified donor 
8M cells were free of complications with transplantation 
of the other organs, multiple infusions of 8M were fol-
lowed by the development of fatal graft-versus-host dis-
ease in one (17%) out of 6 liver transplant recipients; the 
multiple but not the single infusion protocol was discon-
tinued . With a median follow-up of 30 ± 13 months, the 
cytes". These are the same chimerism-driven mecha- overall patient and graft survival as well as graft function 
nisms that are responsible for 
acceptance of organ al- Table 3. Type of O/gan transplantation and different doses of adjuvant bone 
marrow infusion. log rafts in continuously immu-
nosuppressed patients and in 
bone marrow transplant re-
cipients preconditioned with 
cytoablation (see section on 
"allograft acceptance and ac-
Single dose 
Multiple doses 
Total 
Liver Kidney Heart Lung Intestine Multivisceral Total 
71 
6 
77 
85 
28 
113 
27 
3 
30 
19 
5 
24 
23 
o 
23 
4 
o 
4 
229 
42 
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Shapiro R. Corry R. et al: Adjuvant bone marrow infusion in clinical organ transplant recipients. Transplant 
Proc 1998. 30: 1367-1368. used by permission). 
were similar in both the study and control cohorts with 
successful engraftment rates of 82% and 78% for the 
study and control groups, respectively. The actuarial 5-
year graft and patient survival for the 8M augmented 
(single and multiple infusions) and control recipients are 
shown in Figure 11. With a minimum follow-up of at least 
one year, the maintenance immunosuppression required 
to maintain a rejection free-state has been lower in the 
8M-augmented group: daily TAC and steroid doses of 
6.4±3.9 and 5.8±3.3 mg for the study group and 7.1±5 
and 6.2±3.7 mg for the control group. A steroid-free state 
has been achieved with a slightly higher frequency 
among 8M-augmented (64%) than the control (59%) 
group. However. the differences were not statistically 
significant. 
Rejection - In the total study population, the cu-
mulative risk of acute cellular rejection in the first year 
was reduced from 78% in the control population to 62% 
(p=O.037) (Fig. 12A). This effect was more pronounced 
with multiple 8M infusions than with single BM infusions 
(Fig. 128) (29). Of interest. the beneficial effect of 8M 
augmentation was most obvious in heart allograft recipi-
ents with a rejection-free rate of 62% and steroid-resis-
tant rejection rate of only 6.7% compared with 18% and 
8.6%, respectively, for the control group. There also was 
a significant reduction in the development of obliterative 
bronchiolitis with 8M augmentation (3.8%) in lung al-
lograft recipients, compared with contemporaneously 
acquired controls (31%) (26,29). 
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Post-Transplant Lymphoproliferative Disorder 
(PTLD) - Adult recipients who were EBV positive and 
received grafts from EBV-negative donors developed 
PTLD with similar incidences in the study (22%) and 
control group (20%). The disease was reversible, how-
ever, with withdrawal or reduction of immunosuppres-
sion in all but 2 of the study patients. One of these pa-
tients recovered following immunotherapy with autologus 
Iymphokine-activated killer (LAK) cells (30), while the 
other succumbed to disseminated disease. In the pedi-
atric population, none of the study cohort (n=17) devel-
oped PTLD whereas both of the control patients devel-
oped the disease, which was fatal in one. 
Donor Leukocyte Chimerism - BM-augmented 
patients had a 92% incidence of peripheral blood chi-
merism compared with 50% in controls. These findings 
were consistent throughout the duration of follow-up. 
Semi-quantitative PCR studies in cases of male donor-
to-female recipient showed that the levels of donor cell 
chimerism were at least 2 logs higher after BM augmen-
tation, with the greatest difference following multiple BM 
infusions. 
In Vitro Immune Reactivity - Serial one-way 
mixed leukocyte reaction (MLR) determinations were per-
formed, using donor and third party stimulator cells when 
the recipient pretransplant blood samples and donor 
splenocytes were available (31). A higher incidence of 
donor-specific hyporeactivity was found in the 8M-aug-
mented liver (47%), kidney (65%), and lung recipients 
(50%) compared with the control cohorts in which the 
hyporeactivity incidences were 21 %, 38%, and 40%, 
respectively. A reduced incidence of hyporeactivity was 
not seen, however, in heart, small bowel, kidney/pan-
creas, and multiorgan allograft recipients. 
Recurrence of the Non-Neoplastic 
Liver Diseases 
Viral B hepatitis - Historically, the recurrence of 
hepatitis B virus (HBV) infection after liver transplanta-
tion has been associated with unsatisfactory survival 
especially in patients with active viral replication at the 
time of transplantation and in those who were not treated 
with long-term B-virus prophylaxis (32,33). The recent 
use of antiviral agents (eg., lamuvidine) and long-term 
use of passive immunoprophylactic therapy have im-
proved early outcome and reduced the incidence of dis-
ease recurrence. However, long-term follow-up is re-
quired to assess the eventual efficacy of the current pro-
tocols. 
Viral C hepatitis - In a recent study at our center, 
the clinical outcome of 183 liver transplant recipients with 
end-stage liver disease secondary to hepatitis C infec-
tion was compared with a contemporary control group of 
556 patients who underwent transplantation for non-vi-
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Figure 13. The actuarial patient (A) and grajt (B) survival ajter liver transplantation for the hepatitis C patients 
and control (non-viral and non-malignant liver disease) group (From Casavilla A, Rakela J, Kapur S, et al: 
Clinical outcome of patients infected with hepatitis C virus infection on survival ajter primary liver transplanta-
tion under TAe. Liver Transplantation and Surgery 1998, 4:448-454, used by permission). 
ral, non-malignant end-stage hepatic diseases (34). All 
patients were prospectively screened for anti-HCV anti-
bodies and HCV RNA by reverse-transcriptase poly-
merase chain reaction. All recipients were receiving 
low-dose T AC-based immunosuppression. 
Fifty-eight (32%) patients in the HCV group received 
interferon-alpha therapy at some point in their clinical 
course with no or partial response and without increas-
ing the risk of rejection during the course of treatment 
(35). The incidence, time to recurrence, and response 
to interferon-alpha therapy did not differ significantly 
between the various genotypes in our liver transplant 
population, but there was a trend towards higher infec-
tious morbidity and overall mortality in patients with geno-
type 1 b (36,37). 
The cumulative survival rates for the HCV group 
were 80% after one year and 75% after 3 years com-
pared with rates of 84% and 78%, respectively, in the 
control group (p=0.452; Fig. 13A). Primary graft survival 
rates at the same time intervals for the HCV and control 
group were 72% and 77.5% at one year and 67% and 
72% at 3 years, respectively (p=0.144; Fig. 13B). The 
incidence of retransplantation in the HCV group and the 
control group was 12.6% and 10.4%, respectively 
(p=0.42). The cumulative risk for retransplantation over 
time for both groups is shown in Figure 14. None of the 
retransplantations in the HCV recipient group during the 
study period were because of recurrent disease. 
Primary Biliary Cirrhosis (PBC) - The actual risk 
and natural history of recurrent PBC after liver transplan-
tation has been studied in a total of 421 consecutive adult 
recipients of 513 grafts who underwent hepatic replace-
ment at our center for PBC (38). The diagnosis was 
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Figure 14. The cumulative risk of primary graft loss 
among the HCV liver recipients and control group 
(From Casavilla A, Rakela J, Kapur S, et al: Clinical 
outcome of patients infected with hepatitis C virus 
infection on survival ajier primary liver transplanta-
tion under TA C. Liver Transplantation and Surgery 
1998. 4:448-454, used by permission). 
confirmed in all patients by histologic examination of the 
hepatectomy specimen. The immunologic markers were 
typical for PBC in 79.7%. The immunosuppressive regi-
men was based on CY A for 339 grafts and on T AC for 
the other 174. 
With a median follow-up of 5.8 years, the actuarial 
patient survival rate was 82% at one year, 74% at 5 years 
and 63% at 10 years with graft survival rates of 70%, 
63%, and 54%, respectively. Disease recurrence was 
histologically documented in 54 grafts (10.5%). The cri-
teria for recurrence included mononuclear cell portal in-
flammatory infiltrate, portal epithelioid granulomas, lym-
phoid aggregates in the portal tracts, bile duct damage 
and/or florid duct lesions. At time of diagnosis, these 
histologic changes in the allografts were early in all cases. 
Median onset of diagnosis was 67 months from the time 
of liver transplantation. The estimated cumulative risk 
of disease recurrence using the Kaplan-Meier method 
was 1.1% atone year, 7.9% at 5 years, and 21.6% at 10 
years (38). 
With a median follow-up of 91 months from the time 
of transplant and 16 months from the onset of diagnosis, 
only one patient developed hepatic dysfunction serious 
enough to require graft replacement. The risk factors 
analyzed for disease recurrence included occurrence of 
acute/chronic rejection, recipient/donor age and sex, HLA 
mismatch, cold ischemia time, and immunosuppressive 
regimen. Using multivariate Cox regression, the inde-
pendent risk factors were recipient age (p=0.02), cold 
ischemia time (p=0.02), and use ofTAC-based immuno-
suppression (p=0.01). None of the current survivors with 
disease recurrence had clinical or biochemical evidence 
of significant graft dysfunction or extrahepatic disease 
recurrence during the time of observation. 
Primary Sclerosing Cholangitis (PSC) - A total 
of 303 consecutive recipients of 380 hepatic allografts 
treated for PSC during the last 16 years at our institute 
were studied (39). Follow-up evaluation included serial 
liver biopsies and cholangiographic studies in most of 
the recipients. The diagnosis of PSC recurrence was 
based upon the documentation of typical cholangio-
graphic non-anastomotic multiple biliary strictures and 
obstructive cholangiopathy on biopsy in a graft without 
vascular compromise. 
With a mean follow-up of 5.8 years (range: 0.0-15.4), 
the actuarial patient survival was 88% at one year, 73% 
at 5 years, 65% at 10 years, and 61% at 15 years with 
graft survival of 74%,58%,51 %, and 48%, respectively. 
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Recurrence of PSC was documented in 52 (13.7%) al-
lografts with a mean onset of 3.9 years (range: 0.3-9.3). 
The cumulative risk, estimated by the Kaplan-Meier 
method, was 3.6% at one year, 12% at 5 years, 25.3% 
at 10 years, and 25.3% at 15 years (39). 
With a median follow-up of7.6 years from liver trans-
plantation and 3.7 years from onset of diagnosis, none 
of the patients died of recurrent disease although 8 
(15.4%) of the 43 survivors with recurrent PSC already 
have undergone retransplantation and 2 more are await-
ing graft replacement. Old age (p<0.03) and the pres-
ence of inflammatory bowel disease (IBD) (p<0.04) were 
significant risk factors for recurrent hepatic disease. 
Donor age and sex, duration of PSC and lBO, HLA mis-
match, cold ischemia time and baseline immunosuppres-
sion were not significant risk factors for disease recur-
rence. 
Autoimmune hepatitis (AIH) - Only 2 of 91 con-
secutive liver recipients treated at our institution for end-
stage AIH without other concomitant diseases (40) have 
developed histopathologic changes highly suggestive of 
recurrent AIH. The diagnoses of disease recurrence 5.0 
and 5.5 years after transplantation were based upon his-
topathologic changes characteristic of the original dis-
ease, particularly the presence of hepatitic activity with 
plasmacytic infiltrates in the absence of viral infection. 
Neither graft was lost due to disease recurrence (40). 
Hepatic Malignancies 
Primary hepatic tumors that commonly have been 
treated with hepatic replacement are hepatocellular car-
cinoma (HCC), cholangiocarcinoma (hilar, peripheral), 
fibrolamellar hepatoma, and hepatic epithelioid heman-
g ioendothelioma. 
Hepatocellular Carcinoma (HeC) - To estimate 
the recurrence rate of HCC after liver transplantation and 
the associated risk factors, 214 liver recipients with this 
diagnosis were analyzed. Case accrual was from Janu-
ary 1981-December 1992 (41). Of 178 patients who 
survived more than 150 days, 71 (40%) have suffered 
HCC recurrence. Based on 5 risk factors (gender, tu-
mor number, lobar tumor distribution, tumor size, grade 
of vascular invasion), we developed artificial neural net-
work models predicting the likelihood of HCC recurrence 
within one, 2, and 3 consecutive years after transplanta-
tion. 
The following inferences were made. 1) In additiQn 
to the previously known risk factors, gender exerts a 
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powerful effect on HCC recurrence. With identical tu-
mor characteristics, female patients have a lower risk of 
recurrence than males. 2) The grade of vascular inva-
sion is the single most influential risk factor for HCC re-
currence. Conversely, the absence of vascular invasion 
with a maximum tumor diameter <4cm ensures no re-
currence, except in male patients with multiple tumors 
and bilobar distribution. 3) A bilobar tumor distribution 
has a strong impact on HCC recurrence. 4) In general, 
the larger the diameter of the largest tumor, the greater 
the risk of HCC recurrence. 5) Essentially all patients 
with positive margins die from recurrent disease within 
one year after transplantation. 
The influence of postoperative chemotherapy on 
patient survival and recurrence was studied using the 
Kaplan-Meier survival analysis. For the group predicted 
not to suffer HCC recurrence, postoperative chemo-
therapy did not improve patient survival. For the group 
with the intermediate risk of recurrence, a definite but 
not a significant trend was observed of prolonged tu-
mor-free patient survival. The survival benefit of post-
operative chemotherapy was equivocal among patients 
with high risk of recurrence (Fig. 15). 
Fibrolamellar Hepatoma (FH) - This uncommon 
variant of hepatocellular carcinoma is distinguished by 
histopathologic features suggesting greater differentia-
tion than conventional HCC. Over a period of 27 years 
(1968-1995), 13 patients with FH were treated with total 
hepatectomy and liver transplantation, after it was de-
termined that curative partial hepatectomy was not fea-
sible (42). In 6 of these 13 patients total hepatectomy 
was extended to adjacent organs; 2 of the 6 had upper 
abdominal exenteration and organ cluster transplanta-
tion. In one patient, liver transplantation was combined 
with pancreaticoduodenectomy (Whipple procedure). 
Cumulative survival rates at one, 3, 5 and 10 years were 
95%, 45%, 35%, and 20%, respectively. Tumor recur-
rence was confirmed in 9 (69%) of the 13 patients 12-52 
months after transplantation. The liver and lung were 
the most frequent sites of recurrence. Survival thereaf-
ter was up to 43 months. 
The TNM stage at the time of transplantation was 
significantly associated with tumor-free survival. Al-
though tumor-positive lymph nodes were associated with 
a shortened tumor-free survival, the most adverse factor 
was the presence of vascular invasion. As expected, 
total hepatectomy was a viable option when a subtotal 
hepatectomy could not be performed in patients with no 
_100 
~ Chemotherapy 0 
-is 80 
> p<0.01 K~ 
:::::I 60 
tJ) 
~ 40 
.. 
co 
"3 20 E 
-e- Yes 
:::::I 
-T- No U 0 
0 360 720 1,080 1,440 
Patient Survival 
Figure 15. The effect of postoperative chemotherapy 
on the cumulative survival of the HCC patients who 
were at high risk of tumor recurrence ajier liver 
transplantation (From Marsh JW, Dvorchik 1, 
Subotin M, et al: The prediction of risk of recurrence 
and time to recurrence of hepatocellular carcinoma 
after orthotopic liver transplantation: A pilot study. 
Hepatology 1997, 26:444-450, used by permission). 
vascular invasion and without extra-hepatic disease. 
Cholangiocarcinoma (CC) - Cholangiocarcinoma 
is an uncommon malignant neoplasm arising from the 
bile duct epithelium. The tumor location is either hilar 
(Klatskin tumor) or peripheral (intrahepatic). Because of 
the rarity of this malignancy, its prognostic risk factors 
have not been completely analyzed in past reports to 
prospectively assess the risk of recurrence and its im-
pact on survival. Our 15 years (1981-1996) experience 
with a total of 38 patients who had hilar 
cholangiocarcinoma and underwent liver transplantation 
with curative intent were analyzed (43). 
In 27 of these patients, subtotal hepatectomy could 
not be performed either because of the extent of the tu-
mor (n= 14) or because of concomitant advanced cirrho-
sis (n=13). The remaining 11 patients underwent upper 
abdominal exenteration and cluster organ transplanta-
tion (liver with various combinations of pancreas, duode-
num, and short segments of proximal jejunum) under 
even less favorable circumstances: lymph node me-
tastases, direct tumor extension into adjacent organs, 
or regional metastasis (n=10). Dense fibrotic reaction 
caused by preoperative radiation therapy made the in-
traoperative assessment of tumor impossible in one of 
these patients with scleroSing cholangitis. In about half 
of the 38 patients, adjunct external radiation therapy was 
given with or without 5-FU sensitization before or after 
the operation. 
Survival rates for one, 3, and 5 years after the he-
patic or more complex transplantation procedures were 
60%, 32%, and 25%, respectively. Tumor recurrence 
was diagnosed in about 50% of the cases. Although, 
the exact timing of recurrence was often difficult to de-
termine, most of the recurrences were diagnosed within 
the first 3 years. The most common sites of recurrence 
were the hepatic hilum, liver, lung, bone, and skin. 
Univariate analysis revealed that T-3, positive lymph 
nodes, positive surgical margins, and pTNM stage III and 
IV were statistically significant adverse factors. With 
multivariate analysis, pTNM stage 0, I and II, negative 
lymph node, and negative surgical margins were statis-
tically significant good prognostic variables. It was con-
cluded that a 5-year survival rate of 50% could be 
achieved by total hepatectomy and liver transplantation 
for hilar CC when lymph nodes and surgical margins are 
free of tumor and in the absence of distant metastases 
(43). 
This conclusion was validated in an independent 
analysis of a subset of 20 patients with the diagnosis of 
peripheral CC treated during a slightly different period 
(1981-1994) and followed longer (44). With a median 
follow-up of 6.8 years, the overall tumor-free patient sur-
vival rates were 57% at one year, 34% at 3 years, and 
27% at 5 years. However, when patients who did not 
have prognostic factors of positive margins, multiple tu-
mors, and lymph node involvemen! were excluded, pa-
tient survival rates at one, 3 and 5 years were 74%, 64%, 
and 62%. 
Hepatic Epithelioid Hemangioendothelioma -
This multifocal, low-grade malignant neoplasia is char-
acterized by its epithelial-like appearance and vascular 
endothelial histogenesis. The outcome of 16 patients 
treated with liver transplantation was studied to assess 
the potential risk of recurrence (45). With a median fol-
low-up of 4.5 years (range: 1-15) after transplantation, 
the actuarial patient survival was 100% at one year, 88% 
at 3 years, and 73% at 5 years with disease-free sur-
vival rates of 81 %,69%, and 60%, respectively. Involve-
ment of the hilar lymph nodes or vascular invasion did 
not affect survival. The most common sites of recur-
rence were the liver, lung, and bone. 
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HEPATOINTESTINAL AND 
MULTIVISCERAL TRANSPLANTATION 
The potential value of composite abdominal visceral 
transplantation for patients with combined liver/intesti-
nal, and other abdominal visceral organ failure has been 
established (46-48). These procedures also may find a 
place in the treatment of intra-abdominal neoplasms 
(49,50, also see preceding section). To test the 
immunoprotective role on the intestine of the concomi-
tantly transplanted liver, we have included the isolated 
intestinal grafts in the present analysis to serve as a con-
trol group. 
Case Material 
Between May 2, 1990 and August 11, 1997, a total 
of 63 consecutive patients (43 children, 20 adults) re-
ceived either combined liver-intestinal (n=48) or 
multivisceral grafts (n=15) and 35 patients (16 children, 
19 adults) underwent intestinal transplantation alone. All 
of the 48 liver-intestine recipients and the 13 multivisceral 
grafts in which the liver was included (in 2 others it was 
excluded) had advanced hepatic disease that was TPN 
induced in most cases. Ischemia of the upper abdomi-
nal organs (adults) and diffuse irreversible gastrointesti-
nal diseases involving the foregut (mostly children) were 
the usual reasons for choosing multivisceral in prefer-
ence to liver-intestine replacement. Retransplantation 
became necessary in 6 patients; 4 of composite grafts 
and 2 of isolated intestine. 
The clinical features of the allograft recipients are 
summarized in Table 4. The causes of intestinal failure 
were short gut syndrome (80%), dysmotility syndrome 
(11 %), intestinal neoplasm (6%), and enterocyte dysfunc-
tion (3%) with equal distribution among the composite 
visceral and isolated intestinal allograft recipients. The 
causes of the short gut syndrome were variable: pre-
dominantly thrombotic disorders, Crohn's disease, and 
trauma in adults and mostly volvulus, gastroschisis, ne-
crotizing enterocolitis, and intestinal atresia in children. 
Interestingly, 3 of the pediatric patients had undergone 
liver replacement 4-1 0 years prior to intestinal transplan-
tation (46). Forty-six (73%) of the 63 composite allograft 
recipients were United Network of Organ Sharing status 
I (intensive care unit bound), or /I (permanently hospital 
bound). 
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Table 4. Clinical features of intestinal allograft 
recipients. 
Composite Isolated 
Graft Intestine 
Total patients 63 35 
Children/adults 43/20 16/19 
Age (yrs) 
Childrena 4±4 8±5 
Adults 32±9 36±11 
Male/female 34/29 16/19 
Duration of TPN (mo) 39±41 53±47 
Total bilirubin (mg/dl)a 17.4±14 1.2±0.7 
No. of abdominal operationsa 2.7±2.2 5.1±4.3 
Operative time (hr)a 15±4 12±4 
Total of allografts 67 37 
Cold ischemia time (hr)3 9±3 7±2 
HLA (-A, -B, -DR) mismatch 4.7±1.1 4.5±1.2 
Positive cross match 10 (15%) 3 (8%) 
Bone marrow augmentation 12(18%) 8(22%) 
Follow-up (mo) 24+26 23+21 
a p<0.05 
HLA: human leukocyte antigen 
TPN: total parenteral nutrition 
The Donors 
Donor characteristics, and retrieval operations have 
been described previously (46,49,51). Over the past 2 
years, the standard harvesting technique of combined 
liver-intestinal grafts has been modified with inclusion of 
the duodenum in continuity with the jejunum and allograft 
biliary system (Fig. 16). The technique reduces the re-
cipient operative time and avoids the potential risks of 
biliary reconstruction. To avoid humoral GVH complica-
tions (ie., from isoagglutins) every effort is made to find 
donors whose ABO blood types are the same as the re-
cipients'. 
Recipient Operations 
The principles and various modifications of the ge-
neric liver-intestine and multivisceral procedures have 
been reported elsewhere (49,50,52-54). When combined 
liver-intestinal transplantation was performed, preliminary 
portocaval shunt of the native vessels was performed in 
order to alleviate portal hypertension and minimize bleed-
ing during dissection and removal of the host organs. 
Figure 16. Composite liver and intestinal graft with 
preservation of the duodenum in continuity with the 
graft jejunum and hepatic biliary system (From Abu-
Elmagd K, Reyes J, Todo S, et al: Clinical intestinal 
transplantation: New perspectives and immunologic 
considerations. JAm Coll Surg /998,186:512-527, 
used by permission). 
The shunt was left permanently in 69% of the opera-
tions, but in the remaining 31 %, it was disconnected af-
ter graft revascularization and the host portal vein was 
anastomosed to the side of the allograft portal vein. 
Postoperative Care 
Basic immunosuppression was with T AC and pred-
nisone. The perioperative management with emphaSis 
on monitoring of graft rejection, and the long-term graft 
function of these patients has been updated elsewhere 
(46). The humanized anti-IL2 monoclonal antibody 
"Zenapax" has been recently utilized as induction 
immunoprophylaxis. In recent cases, donor leukocyte 
augmentation to facilitate acceptance of the allograft has 
always been utilized when informed consent was ob-
tained from both donor and recipient families. Intestinal 
recipients for whom permission for bone marrow harvest 
could not be obtained, were considered to be prospec-
tive contemporaneous control patients. 
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Figure 17. Kaplan-Meier patient and graft survival 
rates for the total intestinal allograft recipients 
(From Abu-Elmagd K, Reyes J, Todo S, et al: 
Clinical intestinal transplantation: New perspectives 
and immunologic considerations. J Am Call Surg 
1998,186:512-527, used by permission). 
The preparation of the "un purged" BM cell infusate 
from the donor thoracolumbar vertebrae and the infu-
sion method has also been described elsewhere (27). 
The methods used for diagnosis and treatment of rejec-
tion and graft versus host disease were previously de-
scribed (46,55). Protocols for prophylactic and active 
treatment of viral, bacterial, and fungal infections were 
adopted from those developed for liver transplantation 
(54). The newly developed technique of semiquantitative 
peR assay of Epstein-Bar virus (EBV) in the peripheral 
blood has been recently used for early detection and 
monitoring of EBV viremia, which forewarns the devel-
opment of PTLD. 
Survival 
With a mean follow-up of 32 ± 26 months (range, 1-
86), the overall patient survival was 72% at one year 
and 48% at 5 years with graft survival rates of 64% and 
40%, respectively (Fig. 17). Most of the deaths and/or 
graft losses occurred within the first 30 postoperative 
months. The most common causes of failure were in-
fection, rejection, and PTLD. Long-term engraftmentwas 
better achieved with the composite grafts compared with 
the intestine only (Fig. 18). 
Patients with BM augmentation had 89% patient 
survival at 6 months and 72% at 2 years compared with 
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Figure 18. The cumulative survival of the composite 
grafts that contained liver and the intestine only 
(From Abu-Elmagd K, Reyes J, Todo S, et al: 
Clinical intestinal transplantation: New perspectives 
and immunologic considerations. J Am Col! Surg 
1998,186:512-527, used by permission). 
77% and 57% in the control group (Fig. 19A), Impor-
tantly, no mortality occurred beyond the first postopera-
tive year in the BM group and only one of the 4 deaths 
was from a classic complication of immunosuppression. 
In the control group, 4 of the 7 deaths were from oppor-
tunistic infections, and a fifth was from intractable rejec-
tion. 
Survival of the BM-augmented grafts was 75% at 6 
months and 61 % at 2 years compared with 77% and 
52% in the control group (Fig. 19B). It should be noted, 
however, that 2 graft losses in the experimental group 
were caused by management or technical errors. Acute 
rejection was the cause of graft loss in one (5%) of the 
BM-augmented, and 2 (9%) of the control grafts. 
Rejection 
The intestine contained in a composite graft had a 
significantly lower incidence of rejection (66%) compared 
with the isolated intestine (92%) during the first 30 post-
operative days (p=0.004). The median postoperative 
time to the first episode of intestinal rejection was 9 days 
for the isolated intestine, and 19 days for the composite 
grafts (p<O.001). OKT3 was required to treat steroid-re-
sistant rejection in 20 (54%) of the isolated intestine, and 
15 (23%) of the composite grafts (p=0.002). 
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Acute vascular rejection was histologically docu-
mented in 3 of the isolated intestine and none of the 
composite grafts. Although the cumulative rejection 
rate of intestine contained in a composite graft ap-
proached that of isolated intestine during the rest of 
the first postoperative year (Fig. 20A), the rate of com-
posite graft loss from rejection was less than half that 
of the isolated intestine (Fig. 208). Among recipients 
of composite grafts, the incidence of liver rejection 
was less than half that in the intestine (Fig. 21). The 
median time to diagnosis of the first episode was 58 
days, and the mean number of episodes in all cases 
was 0.78±1.5. 
Chronic rejection was histologically diagnosed in 
3 enterectomy specimens for an incidence of 8% with 
isolated intestinal transplantation. The only example 
of chronic rejection of a composite graft was in a pa-
tient whose donor was strongly crossmatch positive; 
Figure 19. Patient (AJ and graft (B) survival rates 
for the bone marrow-augmented and control 
groups (From Abu-Elmagd K, Reyes J, Todo S, et 
al: Clinical intestinal transplantation: New 
perspectives and immunologic considerations. J 
Am Call Surg 1998.186:512-527, used bypermis-
sian). 
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Figure 20. The cumulative risk of intestinal rejection (A), and graft loss jimn rejection (B) for both the isolated 
intestine and composite grafts that contained liver (From Abu-Elmagd K, Reyes J, Todo S, et al: Clinical 
intestinal transplantation: New perspectives and immunologic considerations. J Am Call Surg 1998, 186:512-
527, llsed by permission). 
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Figure 2 J. Cumulative risk of both Intestinal and 
hepatic rejection in the composite visceral allografts 
(From Abu-Elmagd K. Reves J. Todo S. et al: 
Clinical intestinal transplantation: New perspectives 
and immunologic considerations. J Am Call Surg 
1998. 186:512-527, used bv permission). 
both the liver and intestine were affected and the recipi-
ent died of hepatointestinal failure. Because the diag-
nosis of chronic rejection requires study of a transmural 
specimen (not deliberately obtained in biopsies), the 
overall incidence of chronic rejection undoubtedly was 
grossly underestimated (46). 
Bone marrow augmentation increased the risk of 
acute rejection (85%) during the first postoperative month 
compared with the control patients (64%; p=O.20) but 
the overall incidence, frequency and median time of on-
set of the first episode were similar in the 2 groups. OKT3 
was used to control rejection in 4 (20%) of the BM recipi-
ents and 9 (41 %) of the control patients (p=O.2). 
Opportunistic Infections 
Cytomega/ovira/ (CMV) Disease - The risk of 
CMV disease in the isolated and composite graft recipi-
ents was similar, with a combined incidence of 36%. 
There was no difference in the incidence and onset of 
CMV disease in patients given the adjunct BM treatment 
(35%) versus control patients (44%; p=O.8). 
Post-Transplant Lymphoproliferative Disease 
(PTLD) - A total of 20 patients (20%) developed EBV-
associated PTLD. With an incidence of 33%, the 
multivisceral recipients were more prone to PTLD than 
the recipients of liver-intestine (21 %), orthe intestine only 
(11 %; p=O.2). In the BM augmentation trial period, the 
incidence was 10% in the experimental group and 18% 
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in the control patients (p=O.60). By univariate and multi-
variate analyses, the 3 significant risk factors for the 
development of PTLD were young age (children), type 
of intestinal graft (multivisceral), and recipient splenec-
tomy (46) . 
Graft -Versus-Host Disease (GVHD) 
Skin changes suspicious for GVHD were observed 
in 11 patients, but histologically verified in only 5 (5%). 
Two of the 5 patients had received intestine only and the 
other 3 were composite allograft recipients. The GVHD 
was lethal in only one patient, a previously reported child 
(56) with preexisting IgA deficiency who received a liver-
intestine graft. An adult recipient of a multivisceral graft 
developed chronic GVHD (diagnosed by biopsy of the 
buccal mucosa) and eventually died of disseminated 
PTLD with the chronic GVHD still active. The disease 
was self-limited in the other 3 patients, one of whom had 
received adjunct BM (46). 
Chimerism 
The nonavailability of either an appropriate mono-
clonal antibody of the donor-specific primer precluded 
the analysis of chimerism in 4 BM-augmented and 7 con-
trol patients. These studies were feasible in 31 patients. 
At their most recent follow-up, 16 (100%) of 16 BM-aug-
mented, and 12 (80%) of 15 non-augmented recipients 
had donor cell blood chimerism. The 8M-augmented 
recipients had much higher levels of donor cell chimer-
ism than control patients (46). 
Risk Factors 
With univariate and multivariate analyses, 6 risk fac-
tors had been previously reported (57): high T AC blood 
level, steroid bolus therapy, use of OKT3, length of op-
eration, CMV disease, and inclusion of a segment of 
colon with the graft. In addition, the recent analysis has 
added, as adverse factors, the number of intestinal re-
jection episodes, development of PTLD, cold ischemia 
time, number of previous abdominal operations, and male 
donor-to-male recipient. 
Improved Outcome, Cost 
Effectiveness, and Long-Term 
Rehabilitation 
Outcome analysis of the last 115 intestinal and 
multivisceral allografts showed significant improvement 
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in survival during the last 4 years with a cumulative sur-
vival rate of 65% at 4 years (Fig. 22). Such an achieve-
ment may reflect the recent refinement in patient selec-
tion, operative techniques, immunomodulation, and post-
operative management (48). 
The total loaded cost of the 3 different types of in-
testinal transplantation has been significantly reduced 
during the past 4 years. Between 1990-1994, the aver-
age cost was $203,111 for the isolated intestine, 
$252,453 for the combined liver-intestine, and $284,452 
for the multivisceral procedure. These have been re-
duced to an average of $132,285, $214,716, and 
$219,098, respectively. 
Because of the lack of an alternative life-saving treat-
ment for patients with hepatointestinal failure, it is diffi-
cult to put a comparative price on hepatointestinal or 
multivisceral transplantation. However, intestinal trans-
plantation alone can be compared with maintenance 
TPN. Based on Medicare data, the average yearly cost 
ofTPN in 1992 was more than $150,000 per patient, not 
including the cost of frequent hospitalization, medical 
equipment, and nursing care (58). The total dollars spent 
on TPN are escalating yearly because of the growing 
population of home- and hospital-bound patients receiv-
ing this treatment. Based upon these data, isolated in-
testinal transplantation becomes cost-effective by the 
second posttransplant year. 
With a mean follow-up of 3.3 years (range: 1-94 
months), full nutritional autonomy with complete discon-
tinuation ofTPN was successfully achieved in more than 
90% of the recipients. Thirty-one patients are alive with 
good nutrition beyond the third postoperative year and 
18 are beyond the 5-year milestone (48). These indi-
viduals have reported improved quality of life measures 
in comparison to TPN dependency (59,60). 
STRATEGIES FOR 
XENOTRANSPLANTATION 
The immune system did not evolve to frustrate trans-
plant surgeons, but by a survival-driven co-evolution with 
environmental microorganisms (61-65). Nevertheless, 
because of the central role of the major histocompatibil-
ity complex (MHC) in T-cell recognition, the immunology 
of transplantation and infectious disease has much in 
common (66). Thus, the barriers to xenotransplantation 
can be defined in the context of infectious disease. From 
the infectious perspective, the immune system makes 
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Figure 22. Graft survival before and after the J 994 
moratorium (From Abu-Elmagd K, Reyes, Fung JJ, 
et al: Evolution of clinical intestinal transplanta-
tion: Improved outcome and cost effectiveness. 
Transplant Proc, in Press, used by permission). 
strategic decisions comparable to those following trans-
plantation, based on its early distinction of cytopathic 
from the less dangerous non-cytopathic microorganisms. 
Non-Cytopathic Microorganisms and 
Allografts 
Non-cytopathic microorganisms, which are charac-
terized by their entry into host cells, can be accommo-
dated by the host in ways that allow both pathogens and 
host cells to survive. Here, the highest priority is avoid-
ance of tissue damage. Otherwise, complete immune 
destruction of widely disseminated pathogens could kill 
the host. The sophisticated recognition and effector 
mechanisms against overwhelming non-cytopathic infec-
tions (eg., hepatitis B or C virus) are much the same as 
those which have been successfully subverted for or-
gan allotransplantation with the aid of non-specific im-
munosuppressive drugs (see section on "organ engraft-
ment and acquired tolerance"). 
Cytopathic Microorganisms and 
Xenografts 
. 
In contrast, the full force of the host innate and adap-
tive immune capability is urgently mobilized quickly and 
completely to eliminate cytopathic pathogens, without 
much regard for damage to infected host cells. The an-
tigenic signal issued by an a cytopathic infectious invader 
to B cells may come from its densely arranged and or-
dered repetitive epitopes, sometimes aided by li-
popolysaccharides or by other unknown means (sum-
marized in 61,63,64). The first line of defense is domi-
nated by interferons, macrophages, gamma-delta T cells, 
"natural" killer (NK) cells, and by B cells which recognize 
the suspect antigen patterns and may be activated di-
rectly without T-cell help. In addition, non-specific or 
less specific effector mechanisms such as complement, 
interleukins, and phagocytes are promptly involved. 
Similar mechanisms, which are predominantly those 
of innate immunity, are thought to be responsible for the 
hyperacute rejection of xenografts, and of allografts trans-
planted to recipients who have Circulating antigraft anti-
bodies because of ABO incompatibility or prior 
allosensitization (67). The best characterized antigen 
on the cells of discordant xenografts is the surface car-
bohydrate epitope Gal-a (1,3) Gal (68,69) which is chemi-
cally similar to ABO antigens and is found on numerous 
bacteria, protozoa, and viruses (70). 
The transfection of human complement regulatory 
proteins into discordant donor species (71-73) tempo-
rarily delays xenograft destruction, but the other mecha-
nisms of innate immunity promptly cause inexorable re-
jection (74,75). Successful xenotransplantation from 
such donors will require different and combined ap-
proaches whereby antigens are eliminated, or human 
equivalents are introduced. 
Gene knockout procedures have not been done in 
the pig. However, using technologies that may be appli-
cable in pigs, Osman et al (76) working in COS cells 
The unwarranted assumption that stem cell-driven 
hematolymphopoietic chimerism was irrelevant to suc-
cessful whole organ transplantation as currently prac-
ticed led to alternative inadequate explanations of or-
gan allograft acceptance, clouded the meaning of suc-
cessful bone marrow transplantation, and precluded 
for more than 3 decades the development of a cardi-
nal principle applicable to all aspects of transplanta-
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transfected with the Gal-a (1,3) Gal gene have been able 
to reduce the cell surface expression of the gene prod-
uct to negligible levels. This was done by a further double 
transfection with human a-galactosidase and a 1,2 
fucosyl transferase cDNAs. a-galactosidase cleaves a-
linked galactosyl residues of the epitope, thereby expos-
ing subterminal saccharides to which there also are natu-
ral antibodies. However, the a 1,2 fucosyl results in the 
substitution of Gal-a (1,3) Gal with the non-immunogenic 
H substance (ie., the universally tolerated 0 blood group 
antigen) (77) and eliminates complement-mediated ly-
sis of the transgenic COS cells by human serum (76). 
Because what must be done to succeed with 
xenotransplantation has become clear, the prospect of 
using animal organs for human transplantation is brighter 
than at any previous time (78). We have already learned 
empirically with allotransplantation how to work with the 
defense mechanisms developed by nature to control 
noncytopathic infections. Because this approach will 
not work for the xenogeneic antigens that resemble cy-
topathic microorganisms, these antigens in discordant 
animal donors will have to be deleted or changed. It 
remains to be seen whether species restriction of comple-
ment (67,79-81) will necessitate transfection of comple-
ment regulatory proteins to prevent continuous comple-
ment activation. If so, strategies for xenotransplantation 
of the liver will be more complex because this organ is 
the source of most complement. Finally bridge trials with 
xenografts to provide desperately needed temporary 
organ function for candidates waiting for allografts may 
be the best way to obtain information about the efficacy 
of donor species alteration. 
tion. Recognition of this error and the incorporation of 
the chimerism factor into transplantation biology have 
allowed previous enigmas of organ as well as bone 
marrow engraftment to be explained and should allow 
past and future discoveries by basic immunology to 
be more meaningfully exploited to advance clinical 
transplantation, including strategies of 
xenotransplantation. 
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